迈普医学
(301033)
| 流通市值：30.21亿 | | | 总市值：35.94亿 |
| 流通股本：5638.68万 | | | 总股本：6708.27万 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 189,801,626.51 | 78,362,845.65 | 368,830,564.59 | 249,228,235.32 |
| 营业总成本 | 128,608,088.16 | 57,213,511.8 | 255,227,189.08 | 170,015,989.07 |
| 其他经营收益 | | | | |
| 营业利润 | 67,137,460.69 | 23,763,550.87 | 128,009,555.2 | 88,980,940.05 |
| 利润总额 | 66,564,698.97 | 23,766,012.6 | 126,172,398.87 | 87,778,764.59 |
| 净利润 | 56,580,533.57 | 20,715,382.12 | 113,128,438.52 | 75,854,036.84 |
| 每股收益 | | | | |
| 其他综合收益 | -88,615.72 | -67,015.5 | 75,537.46 | 100,175.2 |
| 综合收益总额 | 56,491,917.85 | 20,648,366.62 | 113,203,975.98 | 75,954,212.04 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 361,368,462.18 | 378,251,049.86 | 375,194,183.32 | 322,182,786.75 |
| 非流动资产: | | | | |
| 非流动资产合计 | 539,934,277.19 | 529,576,902.94 | 520,242,380.04 | 522,394,643.03 |
| 资产总计 | 901,302,739.37 | 907,827,952.8 | 895,436,563.36 | 844,577,429.78 |
| 流动负债: | | | | |
| 流动负债合计 | 38,167,492.64 | 34,649,477.7 | 51,567,203.05 | 45,514,788.66 |
| 非流动负债: | | | | |
| 非流动负债合计 | 51,648,868.4 | 53,215,038.77 | 45,810,209.04 | 47,691,877.23 |
| 负债合计 | 89,816,361.04 | 87,864,516.47 | 97,377,412.09 | 93,206,665.89 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 811,486,378.33 | 819,963,436.33 | 798,059,151.27 | 751,370,763.89 |
| 股东权益合计 | 811,486,378.33 | 819,963,436.33 | 798,059,151.27 | 751,370,763.89 |
| 负债和股东权益合计 | 901,302,739.37 | 907,827,952.8 | 895,436,563.36 | 844,577,429.78 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 210,222,268.34 | 94,586,220.96 | 414,731,077.08 | 285,881,257.06 |
| 经营活动现金流出小计 | 162,019,680.43 | 91,383,995.96 | 274,864,398.51 | 202,123,068.5 |
| 经营活动产生的现金流量净额 | 48,202,587.91 | 3,202,225 | 139,866,678.57 | 83,758,188.56 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 258,457,876.45 | 123,096,868.62 | 560,430,012.07 | 475,253,588.15 |
| 投资活动现金流出小计 | 237,825,848.5 | 83,893,494.85 | 706,045,568.8 | 542,900,968.23 |
| 投资活动产生的现金流量净额 | 20,632,027.95 | 39,203,373.77 | -145,615,556.73 | -67,647,380.08 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | 12,626,905.05 | 12,955,659.6 |
| 筹资活动现金流出小计 | 46,778,205.9 | - | 40,822,373.55 | 40,653,893.01 |
| 筹资活动产生的现金流量净额 | -46,778,205.9 | - | -28,195,468.5 | -27,698,233.41 |
| 汇率变动对现金及现金等价物的影响 | -648,129.59 | -360,776.12 | 321,959.72 | 476,542.53 |
| 现金及现金等价物净增加额 | 21,408,280.37 | 42,044,822.65 | -33,622,386.94 | -11,110,882.4 |
| 期末现金及现金等价物余额 | 41,003,494.7 | 61,640,036.98 | 19,595,214.33 | 42,106,718.87 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 21,408,280.37 | - | -33,622,386.94 | - |
最新报告期：2026-08-24| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 平安证券 | 叶寅,倪亦道,裴晓鹏 | 2.16 | 2.69 | 3.29 | 2026-08-24 |
| 广发证券 | 王稼宸,罗佳荣 | 2.29 | 3.37 | 5.02 | 2026-08-21 |